As current BC screening focuses on detecting the associated genetic factors, including ATM (Ataxia Telangiectasia Mutated), CHEK2 (checkpoint kinase 2), Breast Cancer 1 (BRCA1), Breast Cancer 2 (BRCA2), and PALB2 (partner and localizer of BRCA2) [5], this necessitated the need for the discovery of BC biomarkers with sufficient diagnostic and prognostic sensitivity and specificity. The gene discussed is PALB2; the disease is breast cancer.